BiOasis Technologies

Provista Diagnostics has formed its scientific advisory board, appointing Karen Anderson, Carlos Arteaga, Robert Benezra, Andrew Dannenberg, and Joshua LaBaer.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The assay, which uses SISCAPA MRM-MS to measure serum levels of melanotransferrin – a protein that a number of studies have tied to Alzheimer's – marks an example of mass spec-based proteomics' ongoing move into the clinical setting.

The latest pact will focus on the use of p97 as a delivery system to transport Alzheimer's drugs across the blood-brain barrier. Last month, Bioasis and UBC inked a first research collaboration to develop and test a p97-based blood test to diagnose and monitor Alzheimer's.

The Canadian firm will use the funds to support further development of its diagnostic assays for Alzheimer's disease.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.